Small Nucleolar RNAs (snoRNAs)-Based Risk Score Classifier Predicts Overall Survival in Bladder Carcinoma

He, Rong‐Quan; Huang, Zhi‐Guang; Zhai, Gao-Qiang; Huang, Su-Hua; Gu, Yutong; Chen, Gang; Ma, Jie; Cheng, Jian; Yan, Haibiao; Li, Sheng‐Hua

doi:10.12659/msm.926273

Cited by 2 publications

(1 citation statement)

References 36 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SNORD59A was a positive prognostic factor in bladder cancer. 35 Shang et al 36 found that SNORD63 was elevated in the plasma and tumour tissues of patients with clear cell renal cell carcinoma, such that SNORD63 can be used as a diagnostic marker. The expression of SNORD12C was significantly increased in colorectal cancer, 37 and it played an important role in tumourigenesis, through the ZFAS1-NOP58-SNORD12C/78-EIF4A3/LAMC2 signaling axis.…”

Section: Discussionmentioning

confidence: 99%

Identification of tumour immune infiltration-associated snoRNAs (TIIsno) for predicting prognosis and immune landscape in patients with colon cancer via a TIIsno score model

et al. 2022

View full text Add to dashboard Cite

Background Colon cancer (CC) is the leading cause of tumour-related death worldwide. SnoRNA plays a critical role in the tumour microenvironment. The tumour microenvironment can be shaped by tumour-infiltrating immune cells, which control the destiny of immunotherapy efficacy. This study uniquely focused on snoRNAs derived from immune cells to identify new biomarkers for immune landscape.Methods A novel computational framework was initiated for identifying tumour immune infiltration-associated snoRNAs (TIIsno) signatures and developed a TIIsno score model from integrative snoRNA profiling analysis of 21 purified immune cell lines, 43 colon cancer cell lines, and three datasets (training, test, real-world validation set).Findings Our study found that a high TIIsno score was associated with poor CC prognosis. TIIsno scores were seen to be negatively correlated with (I) the infiltration level of most immune cells, (II) the inhibitory immune checkpoints expression level, and (III) the immune score. These findings, taken together with the observation that TIIsno score is lower in MSI-H patients, suggests that patients with a low TIIsno score may have a better response to immunotherapy.Interpretation In conclusion, we successfully identified TIIsno and constructed a TIIsno score model, a new potential biomarker of immunotherapy response, which can effectively predict the prognosis of CC patients as well.

show abstract

Section: Discussionmentioning

confidence: 99%